Hemophilia A

Genetic MONDO:0010602 Pathograph 20 Bleeding Disorder Coagulation Disorder

Hemophilia A is an X-linked inherited coagulation disorder caused by pathogenic F8 variants that reduce functional factor VIII, impair intrinsic tenase activity, limit thrombin generation and fibrin clot stability, and produce trauma-related or spontaneous bleeding.

Ask OpenScientist

Ask a research question about Hemophilia A. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
1
Inheritance
5
Pathophysiology
0
Histopathology
7
Phenotypes
20
Pathograph
1
Genes
7
Treatments
3
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
1
Deep Research
🏷

Classifications

Harrison's Chapter
hematologic disorder coagulation disorder hereditary disease
👪

Inheritance

1
X-linked recessive HP:0001419
X-linked recessive inheritance
Show evidence (1 reference)
PMID:26743572 SUPPORT Human Clinical
"Hemophilia A (HA) is an X-linked recessive congenital bleeding disorder with an occurrence of 1 in 5,000 male births"
This supports the inheritance pattern and male birth incidence for congenital hemophilia A.
◆

Subtypes

3
Severe Hemophilia A MONDO:0015719
Factor VIII activity less than 1%, spontaneous bleeding episodes.
Moderate Hemophilia A MONDO:0015720
Factor VIII activity 1-5%, bleeding with minor trauma.
Mild Hemophilia A MONDO:0015721
Factor VIII activity 5-40%, bleeding with surgery or major trauma.
⚙

Pathophysiology

5
Factor VIII Deficiency
Mutations in the F8 gene cause deficient or dysfunctional factor VIII protein. Factor VIII is a cofactor for factor IXa in the intrinsic coagulation pathway, essential for thrombin generation and fibrin clot formation.
liver sinusoidal endothelial cell link
Blood Coagulation link ↓ DECREASED
Downstream
Intrinsic Tenase Dysfunction
Prolonged aPTT
Show evidence (3 references)
PMID:3096583 SUPPORT
"FVIII acts as a cofactor in the factor Xa-generating enzyme complex of the intrinsic coagulation cascade."
Review establishes the molecular role of Factor VIII as a cofactor in the intrinsic pathway.
PMID:34197690 SUPPORT
"Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
Clinical review confirms Factor VIII deficiency as the cause of hemophilia A.
PMID:26743572 SUPPORT In Vitro
"Importantly, both F8 transcription and FVIII secretion were rescued in the candidate cell types for HA gene therapy including endothelial cells (ECs) and mesenchymal stem cells (MSCs) derived from the gene-corrected iPSCs."
Gene-correction experiments in patient-derived iPSCs support endothelial-lineage cells as relevant FVIII-producing cells.
Alloimmune FVIII Inhibitor Response
Therapeutic exposure to exogenous factor VIII can trigger neutralizing anti-FVIII antibodies that render FVIII replacement less effective and increase bleeding morbidity.
immune response link ↑ INCREASED
Downstream
FVIII Inhibitor Development
Show evidence (1 reference)
PMID:29482894 SUPPORT Human Clinical
"Nowadays, the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A."
Review directly identifies neutralizing anti-FVIII antibodies after exogenous FVIII exposure as a major hemophilia A treatment complication.
Impaired Thrombin Generation
Without functional factor VIII, the intrinsic tenase complex cannot form efficiently. This results in inadequate thrombin generation and unstable fibrin clot formation, leading to prolonged bleeding.
Blood Coagulation link ↓ DECREASED
Downstream
Unstable Fibrin Clot Formation
Show evidence (1 reference)
PMID:11806995 SUPPORT In Vitro
"pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro."
Study demonstrates that thrombin generation is fundamentally impaired in hemophilia A blood even with bypass therapy attempts.
Intrinsic Tenase Dysfunction
Loss of factor VIIIa cofactor activity weakens the intrinsic tenase complex formed by factor VIIIa and factor IXa, reducing factor Xa generation and the downstream thrombin burst required for hemostasis.
intrinsic pathway of blood coagulation link ↓ DECREASED
Downstream
Impaired Thrombin Generation
Show evidence (1 reference)
PMID:19563500 SUPPORT Human Clinical
"In the absence of factor VIIIa (as in hemophilia A), the intrinsic tenase complex (factor VIIIa-factor IXa) is unable to generate the additional factor Xa that is required for the burst (propagation) of thrombin generation through the prothrombinase complex (factor Va-factor Xa)"
Whole-blood thrombin generation study explains the direct mechanism by which FVIII absence limits tenase output.
Unstable Fibrin Clot Formation
Reduced thrombin generation leaves hemophilia A clots more porous and less mechanically stiff, limiting durable hemostasis after vascular or tissue injury.
Fibrin Clot Formation link ↓ DECREASED
Downstream
Hemarthrosis
Prolonged Bleeding
Easy Bruising
Muscle Hematomas
Show evidence (1 reference)
PMID:29713693 SUPPORT In Vitro
"Effective clot formation can be achieved in HemA by replacement therapy, which alters the architecture of the fibrin network and associated cells, thus increasing clot stiffness and decreasing clot permeability."
In vitro and mouse clot-structure experiments support clot instability as the immediate phenotype-producing step downstream of FVIII deficiency.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hemophilia A Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Blood 4
Hemarthrosis VERY_FREQUENT Joint hemorrhage (HP:0005261)
Recurrent joint bleeds leading to arthropathy
Sequelae: Hemophilic Arthropathy
Show evidence (1 reference)
PMID:34197690 SUPPORT
"Recurrent joint bleeding (hemarthrosis) is the most frequent clinical manifestation of severe hemophilia."
Review confirms hemarthrosis as the primary clinical feature of severe hemophilia.
Prolonged Bleeding VERY_FREQUENT Abnormal bleeding (HP:0001892)
After trauma or surgery
Show evidence (1 reference)
PMID:27890816 PARTIAL
"Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
Review establishes that bleeding following trauma is a defining feature of hemophilia.
Easy Bruising VERY_FREQUENT Bruising susceptibility (HP:0000978)
Show evidence (1 reference)
PMID:27890816 PARTIAL Human Clinical
"Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
Spontaneous and trauma-related bleeding in hemophilia manifests as easy bruising due to defective clot formation.
Prolonged aPTT VERY_FREQUENT Prolonged partial thromboplastin time (HP:0003645)
Activated partial thromboplastin time prolonged, PT normal
Show evidence (1 reference)
PMID:36409923 PARTIAL
"Hemophilia A is a bleeding disorder caused by deficiency or low activity of circulating factor VIII characterized by prolonged blood coagulation time and often spontaneous bleeding."
Study confirms prolonged coagulation time as a defining characteristic of hemophilia A.
Musculoskeletal 2
Hemophilic Arthropathy FREQUENT Arthropathy (HP:0003040)
Chronic joint remodeling, pain, and loss of function after repeated joint bleeding.
Show evidence (1 reference)
PMID:34197690 SUPPORT Human Clinical
"Unless appropriately managed, even subclinical hemarthrosis can lead to the development of hemophilic arthropathy, a disabling condition characterized by joint remodelling, chronic pain, and a reduced quality of life, and eventually requires joint replacement."
Review directly describes hemophilic arthropathy as the downstream chronic joint phenotype after hemarthrosis.
Muscle Hematomas FREQUENT Intramuscular hematoma (HP:0012233)
Deep muscle bleeding can cause compartment syndrome
Show evidence (1 reference)
PMID:19563500 SUPPORT Human Clinical
"We studied factor(F) VIII deficient individuals (11 mild, 4 moderate and 12 severe) with a well-characterized 5-year bleeding history that included haemarthrosis, soft tissue haematoma and annual FVIII concentrate usage."
Hemophilia A cohort bleeding histories explicitly included soft tissue hematoma, supporting deep muscle or soft-tissue bleeding as a phenotype.
Other 1
FVIII Inhibitor Development FREQUENT Anti-factor VIII antibody positivity (HP:6000494)
Neutralizing anti-FVIII antibodies complicate replacement therapy, especially in severe hemophilia A.
Show evidence (1 reference)
PMID:29482894 SUPPORT Human Clinical
"Nowadays, the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A."
Review directly supports anti-FVIII inhibitor development as a frequent complication in severe hemophilia A.
🧬

Genetic Associations

1
F8 pathogenic variants (Causative X-linked loss-of-function variants)
X-linked recessive
Show evidence (2 references)
PMID:26743572 SUPPORT Other
"HA is caused by a deficiency of the clotting factor VIII (FVIII), encoded by the factor VIII gene (F8)"
This supports F8 as the causal gene and factor VIII deficiency as the immediate molecular defect.
CGGV:assertion_d4578f11-b635-45f4-8034-310fca5fe960-2019-07-24T160000.000Z SUPPORT Other
"F8 | HGNC:3546 | hemophilia A | MONDO:0010602 | XL | Definitive"
ClinGen classifies the F8-hemophilia A gene-disease relationship as definitive with X-linked inheritance.
💊

Treatments

7
Factor VIII Replacement
Action: coagulation factor VIII replacement therapy MAXO:0020000
Recombinant or plasma-derived factor VIII concentrate for bleeding episodes and prophylaxis.
Mechanism Target:
RESTORES Factor VIII Deficiency — Replaces missing or deficient factor VIII activity upstream of intrinsic tenase dysfunction.
Show evidence (1 reference)
PMID:31846611 SUPPORT Human Clinical
"Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals."
Review directly supports FVIII replacement prophylaxis as standard-of-care hemophilia A treatment.
Emicizumab
Action: pharmacotherapy MAXO:0000058
Bispecific antibody mimicking factor VIII function, subcutaneous prophylaxis.
Mechanism Target:
BYPASSES Intrinsic Tenase Dysfunction — Bridges activated factor IX and factor X to substitute for missing activated factor VIII cofactor function.
Show evidence (1 reference)
PMID:30157389 SUPPORT
"Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis."
Phase 3 HAVEN 3 trial demonstrates emicizumab mechanism and efficacy in hemophilia A without inhibitors.
Immune Tolerance Induction
Action: pharmacotherapy MAXO:0000058
Repeated FVIII administration protocol intended to downregulate anti-FVIII antibodies and eradicate inhibitors.
Mechanism Target:
INHIBITS Alloimmune FVIII Inhibitor Response — Repeated FVIII exposure under immune tolerance protocols downregulates the established inhibitor response.
Show evidence (2 references)
PMID:29482894 SUPPORT Human Clinical
"Using a protocol called "immune tolerance induction" (ITI), the repeated and frequent administration of FVIII under non-inflammatory conditions downregulates the established antibody response and induces immune tolerance."
Review directly supports ITI as an inhibitor-eradication strategy for hemophilia A.
PMID:26770953 SUPPORT Human Clinical
"Complete tolerance was achieved in 14 of 17 patients (83%)."
Retrospective severe hemophilia A inhibitor cohort quantifies ITI success, supporting the expected 60-80% range from the research artifact.
Bypass Therapy
Action: pharmacotherapy MAXO:0000058
Activated prothrombin complex concentrate or recombinant activated factor VII for bleeding in patients with active inhibitors.
Mechanism Target:
BYPASSES Intrinsic Tenase Dysfunction — aPCC and rFVIIa promote hemostasis through alternative coagulation activation when FVIII activity is inhibited.
Show evidence (1 reference)
PMID:22285208 SUPPORT Human Clinical
"Activated prothrombin complex concentrate (aPCC) and recombinant Factor VIIa (rFVIIa) are 2 bypassing agents commonly used for treating acute bleeds in hemophiliac patients with inhibitors."
Systematic review directly identifies aPCC and rFVIIa as bypassing agents for acute bleeding in hemophilia patients with inhibitors.
Desmopressin (DDAVP)
Action: pharmacotherapy MAXO:0000058
Releases endogenous factor VIII, useful in mild hemophilia A.
Mechanism Target:
RESTORES Factor VIII Deficiency — Raises endogenous factor VIII availability in responsive non-severe hemophilia A.
Show evidence (1 reference)
PMID:12640572 SUPPORT
"Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction."
Review confirms desmopressin as a widely used hemostatic agent in mild hemophilia A.
Antifibrinolytics
Action: pharmacotherapy MAXO:0000058
Tranexamic acid or aminocaproic acid as adjunctive therapy.
Show evidence (1 reference)
PMID:26704192 SUPPORT
"Overall, the two included trials showed a beneficial effect of tranexamic acid and EACA, administered systemically, in reducing the number of bleedings, the amount of blood loss and the need for therapeutic clotting factor concentrates."
Cochrane systematic review confirms beneficial effect of tranexamic acid and aminocaproic acid in reducing bleeding in hemophilia patients.
Gene Therapy
Action: gene therapy MAXO:0001001
Emerging treatment using AAV vectors to deliver functional F8 gene.
Mechanism Target:
RESTORES Factor VIII Deficiency — Supplies a functional F8 expression cassette to restore endogenous factor VIII production.
Show evidence (1 reference)
PMID:35294811 SUPPORT
"In patients with severe hemophilia A, valoctocogene roxaparvovec treatment provided endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis."
Phase 3 GENEr8-1 trial demonstrates AAV5-based gene therapy efficacy in severe hemophilia A.
🔬

Biochemical Markers

3
Factor VIII Activity (Decreased)
Context: Severe less than 1%, moderate 1-5%, mild 5-40%
aPTT (Elevated)
Context: Prolonged, corrects with mixing study
PT/INR (Normal)
Context: Extrinsic pathway intact
{ }

Source YAML

click to show 
name: Hemophilia A
creation_date: '2026-01-06T04:44:07Z'
updated_date: '2026-04-26T05:37:10Z'
category: Genetic
parents:
- Bleeding Disorder
- Coagulation Disorder
disease_term:
  preferred_term: hemophilia A
  term:
    id: MONDO:0010602
    label: hemophilia A
description: >-
  Hemophilia A is an X-linked inherited coagulation disorder caused by
  pathogenic F8 variants that reduce functional factor VIII, impair intrinsic
  tenase activity, limit thrombin generation and fibrin clot stability, and
  produce trauma-related or spontaneous bleeding.
has_subtypes:
- name: Severe Hemophilia A
  subtype_term:
    preferred_term: severe hemophilia A
    term:
      id: MONDO:0015719
      label: severe hemophilia A
  description: Factor VIII activity less than 1%, spontaneous bleeding episodes.
- name: Moderate Hemophilia A
  subtype_term:
    preferred_term: moderately severe hemophilia A
    term:
      id: MONDO:0015720
      label: moderately severe hemophilia A
  description: Factor VIII activity 1-5%, bleeding with minor trauma.
- name: Mild Hemophilia A
  subtype_term:
    preferred_term: mild hemophilia A
    term:
      id: MONDO:0015721
      label: mild hemophilia A
  description: Factor VIII activity 5-40%, bleeding with surgery or major trauma.
prevalence:
- population: Males in high-income-country registry meta-analysis
  percentage: 17.1 per 100,000 males
  notes: >-
    Meta-analysis of national registries estimated hemophilia A prevalence at
    17.1 per 100,000 males for all severities and 24.6 per 100,000 males at
    birth.
  evidence:
  - reference: PMID:31499529
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A"
    explanation: This registry-based meta-analysis provides the clearest pooled prevalence estimate for hemophilia A among living males.
  - reference: PMID:31499529
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence at birth (per 100 000 males) is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A"
    explanation: The same study adds birth prevalence, which helps contextualize disease burden before survival effects.
- population: United States males
  percentage: 12 per 100,000 males
  notes: >-
    U.S. surveillance through hemophilia treatment centers estimated a period
    prevalence of 12 per 100,000 males for hemophilia A and an overall
    incidence of 1 case per 4,334 live male births for hemophilia.
  evidence:
  - reference: PMID:32329553
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results:  During the period, 21 748 males with haemophilia visited the HTCs resulting in an age-adjusted prevalence of 15.7 cases per 100 000 males (12 for haemophilia A and 3.7 for haemophilia B)."
    explanation: This U.S. surveillance study directly reports age-adjusted prevalence for hemophilia A among males.
  - reference: PMID:32329553
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on 9587 males born during the index period, the average haemophilia incidence was 1 case per 4334 live male births."
    explanation: The same surveillance study provides a complementary incidence estimate from a modern U.S. cohort.
inheritance:
- name: X-linked recessive
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:26743572
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia A (HA) is an X-linked recessive congenital bleeding disorder with an occurrence of 1 in 5,000 male births"
    explanation: This supports the inheritance pattern and male birth incidence for congenital hemophilia A.
pathophysiology:
- name: Factor VIII Deficiency
  description: >
    Mutations in the F8 gene cause deficient or dysfunctional factor VIII protein.
    Factor VIII is a cofactor for factor IXa in the intrinsic coagulation pathway,
    essential for thrombin generation and fibrin clot formation.
  gene:
    preferred_term: F8
    term:
      id: hgnc:3546
      label: F8
  cell_types:
  - preferred_term: liver sinusoidal endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Blood Coagulation
    term:
      id: GO:0007596
      label: blood coagulation
    modifier: DECREASED
  evidence:
  - reference: PMID:3096583
    reference_title: "The physiology and pathophysiology of the factor VIII complex."
    supports: SUPPORT
    snippet: "FVIII acts as a cofactor in the factor Xa-generating enzyme complex of the intrinsic coagulation cascade."
    explanation: Review establishes the molecular role of Factor VIII as a cofactor in the intrinsic pathway.
  - reference: PMID:34197690
    reference_title: "Hemophilic arthropathy: Current knowledge and future perspectives."
    supports: SUPPORT
    snippet: "Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
    explanation: Clinical review confirms Factor VIII deficiency as the cause of hemophilia A.
  - reference: PMID:26743572
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Importantly, both F8 transcription and FVIII secretion were rescued in the candidate cell types for HA gene therapy including endothelial cells (ECs) and mesenchymal stem cells (MSCs) derived from the gene-corrected iPSCs."
    explanation: Gene-correction experiments in patient-derived iPSCs support endothelial-lineage cells as relevant FVIII-producing cells.
  downstream:
  - target: Intrinsic Tenase Dysfunction
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19563500
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the intrinsic tenase complex (factor VIIIa-factor IXa) is unable to generate the additional factor Xa that is required for the burst (propagation) of thrombin generation"
      explanation: This directly links missing factor VIIIa to impaired intrinsic tenase amplification.
  - target: Prolonged aPTT
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired intrinsic pathway activity measured by activated partial thromboplastin time
- name: Alloimmune FVIII Inhibitor Response
  description: >-
    Therapeutic exposure to exogenous factor VIII can trigger neutralizing
    anti-FVIII antibodies that render FVIII replacement less effective and
    increase bleeding morbidity.
  biological_processes:
  - preferred_term: immune response
    term:
      id: GO:0006955
      label: immune response
    modifier: INCREASED
  evidence:
  - reference: PMID:29482894
    reference_title: "Review of immune tolerance induction in hemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nowadays, the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A."
    explanation: Review directly identifies neutralizing anti-FVIII antibodies after exogenous FVIII exposure as a major hemophilia A treatment complication.
  downstream:
  - target: FVIII Inhibitor Development
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29482894
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This antibody response renders FVIII replacement therapy ineffective, thereby increasing the risk for uncontrollable bleeding and morbidity, decreasing quality of life and increasing healthcare costs."
      explanation: This links the alloimmune inhibitor response to the clinically recognized inhibitor complication.
- name: Impaired Thrombin Generation
  description: >
    Without functional factor VIII, the intrinsic tenase complex cannot form
    efficiently. This results in inadequate thrombin generation and unstable
    fibrin clot formation, leading to prolonged bleeding.
  biological_processes:
  - preferred_term: Blood Coagulation
    term:
      id: GO:0007596
      label: blood coagulation
    modifier: DECREASED
  evidence:
  - reference: PMID:11806995
    reference_title: "Mechanism of factor VIIa-dependent coagulation in hemophilia blood."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro."
    explanation: Study demonstrates that thrombin generation is fundamentally impaired in hemophilia A blood even with bypass therapy attempts.
  downstream:
  - target: Unstable Fibrin Clot Formation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29713693
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "FVIII profoundly affected HemA clot structure and physical properties; added FVIII converted the open and porous fibrin meshwork and low stiffness of HemA clots to a highly branched and dense meshwork with higher stiffness."
      explanation: This links factor VIII-dependent thrombin generation to the physical stability of the fibrin clot.
- name: Intrinsic Tenase Dysfunction
  description: >-
    Loss of factor VIIIa cofactor activity weakens the intrinsic tenase complex
    formed by factor VIIIa and factor IXa, reducing factor Xa generation and the
    downstream thrombin burst required for hemostasis.
  biological_processes:
  - preferred_term: intrinsic pathway of blood coagulation
    term:
      id: GO:0007597
      label: blood coagulation, intrinsic pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:19563500
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the absence of factor VIIIa (as in hemophilia A), the intrinsic tenase complex (factor VIIIa-factor IXa) is unable to generate the additional factor Xa that is required for the burst (propagation) of thrombin generation through the prothrombinase complex (factor Va-factor Xa)"
    explanation: Whole-blood thrombin generation study explains the direct mechanism by which FVIII absence limits tenase output.
  downstream:
  - target: Impaired Thrombin Generation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19563500
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our empirical study in CTI-inhibited whole blood shows that the MaxL of thrombin generation appears to correlate with the bleeding phenotype of haemophilia A."
      explanation: This links deficient thrombin generation to clinical bleeding severity.
- name: Unstable Fibrin Clot Formation
  description: >-
    Reduced thrombin generation leaves hemophilia A clots more porous and less
    mechanically stiff, limiting durable hemostasis after vascular or tissue
    injury.
  biological_processes:
  - preferred_term: Fibrin Clot Formation
    term:
      id: GO:0072378
      label: blood coagulation, fibrin clot formation
    modifier: DECREASED
  evidence:
  - reference: PMID:29713693
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Effective clot formation can be achieved in HemA by replacement therapy, which alters the architecture of the fibrin network and associated cells, thus increasing clot stiffness and decreasing clot permeability."
    explanation: In vitro and mouse clot-structure experiments support clot instability as the immediate phenotype-producing step downstream of FVIII deficiency.
  downstream:
  - target: Hemarthrosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - defective durable hemostasis at mechanically stressed synovial joints
    evidence:
    - reference: PMID:34197690
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Recurrent joint bleeding (hemarthrosis) is the most frequent clinical manifestation of severe hemophilia."
      explanation: This supports joint bleeding as a major downstream manifestation of defective clot formation.
  - target: Prolonged Bleeding
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27890816
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
      explanation: This supports prolonged spontaneous and trauma-related bleeding as the clinical manifestation of clotting-factor deficiency.
  - target: Easy Bruising
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - soft-tissue bleeding after minor trauma
  - target: Muscle Hematomas
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - deep soft-tissue bleeding after inadequate clot stabilization
phenotypes:
- name: Hemarthrosis
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Recurrent joint bleeds leading to arthropathy
  phenotype_term:
    preferred_term: Hemarthrosis
    term:
      id: HP:0005261
      label: Joint hemorrhage
  evidence:
  - reference: PMID:34197690
    reference_title: "Hemophilic arthropathy: Current knowledge and future perspectives."
    supports: SUPPORT
    snippet: "Recurrent joint bleeding (hemarthrosis) is the most frequent clinical manifestation of severe hemophilia."
    explanation: Review confirms hemarthrosis as the primary clinical feature of severe hemophilia.
  sequelae:
  - target: Hemophilic Arthropathy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27890816
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Spontaneous bleeding shows a predilection for joints, and repeated hemarthroses lead to a disabling condition called hemophilic arthropathy."
      explanation: This directly supports recurrent hemarthrosis as the cause of hemophilic arthropathy.
- name: Hemophilic Arthropathy
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Chronic joint remodeling, pain, and loss of function after repeated joint bleeding.
  phenotype_term:
    preferred_term: Hemophilic arthropathy
    term:
      id: HP:0003040
      label: Arthropathy
  evidence:
  - reference: PMID:34197690
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unless appropriately managed, even subclinical hemarthrosis can lead to the development of hemophilic arthropathy, a disabling condition characterized by joint remodelling, chronic pain, and a reduced quality of life, and eventually requires joint replacement."
    explanation: Review directly describes hemophilic arthropathy as the downstream chronic joint phenotype after hemarthrosis.
- name: Prolonged Bleeding
  category: Hematologic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: After trauma or surgery
  phenotype_term:
    preferred_term: Prolonged Bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: PMID:27890816
    reference_title: "Pathophysiology of hemophilic arthropathy and potential targets for therapy."
    supports: PARTIAL
    snippet: "Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
    explanation: Review establishes that bleeding following trauma is a defining feature of hemophilia.
- name: Easy Bruising
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Easy Bruising
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: PMID:27890816
    reference_title: "Pathophysiology of hemophilic arthropathy and potential targets for therapy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
    explanation: Spontaneous and trauma-related bleeding in hemophilia manifests as easy bruising due to defective clot formation.
- name: Muscle Hematomas
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Deep muscle bleeding can cause compartment syndrome
  phenotype_term:
    preferred_term: Muscle Hematoma
    term:
      id: HP:0012233
      label: Intramuscular hematoma
  evidence:
  - reference: PMID:19563500
    reference_title: "Thrombin generation and bleeding in haemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We studied factor(F) VIII deficient individuals (11 mild, 4 moderate and 12 severe) with a well-characterized 5-year bleeding history that included haemarthrosis, soft tissue haematoma and annual FVIII concentrate usage."
    explanation: Hemophilia A cohort bleeding histories explicitly included soft tissue hematoma, supporting deep muscle or soft-tissue bleeding as a phenotype.
- name: FVIII Inhibitor Development
  category: Hematologic
  frequency: FREQUENT
  notes: Neutralizing anti-FVIII antibodies complicate replacement therapy, especially in severe hemophilia A.
  phenotype_term:
    preferred_term: Anti-factor VIII antibody positivity
    term:
      id: HP:6000494
      label: Anti-factor VIII antibody positivity
  evidence:
  - reference: PMID:29482894
    reference_title: "Review of immune tolerance induction in hemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nowadays, the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A."
    explanation: Review directly supports anti-FVIII inhibitor development as a frequent complication in severe hemophilia A.
- name: Prolonged aPTT
  category: Laboratory
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Activated partial thromboplastin time prolonged, PT normal
  phenotype_term:
    preferred_term: Prolonged aPTT
    term:
      id: HP:0003645
      label: Prolonged partial thromboplastin time
  evidence:
  - reference: PMID:36409923
    reference_title: "Phenotypic variation in severe hemophilia A is related to endogenous thrombin potential and plasma levels of factor VII."
    supports: PARTIAL
    snippet: "Hemophilia A is a bleeding disorder caused by deficiency or low activity of circulating factor VIII characterized by prolonged blood coagulation time and often spontaneous bleeding."
    explanation: Study confirms prolonged coagulation time as a defining characteristic of hemophilia A.
biochemical:
- name: Factor VIII Activity
  presence: Decreased
  context: Severe less than 1%, moderate 1-5%, mild 5-40%
- name: aPTT
  presence: Elevated
  context: Prolonged, corrects with mixing study
- name: PT/INR
  presence: Normal
  context: Extrinsic pathway intact
genetic:
- name: F8 pathogenic variants
  gene_term:
    preferred_term: F8
    term:
      id: hgnc:3546
      label: F8
  association: Causative X-linked loss-of-function variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  inheritance:
  - name: X-linked recessive
    inheritance_term:
      preferred_term: X-linked recessive inheritance
      term:
        id: HP:0001419
        label: X-linked recessive inheritance
  variants:
  - name: F8 intron 22 inversion
    type: structural_variant
    clinical_significance: PATHOGENIC
    description: >-
      Recurrent F8 structural inversion that splits the gene and is a common
      cause of severe hemophilia A.
    evidence:
    - reference: PMID:7662970
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A total of 2,093 patients with severe hemophilia A were studied; of those, 740 (35%) had a type 1 (distal) factor VIII inversion, and 140 (7%) showed a type 2 (proximal) inversion."
      explanation: International severe hemophilia A cohort quantifies recurrent factor VIII inversions as a major variant class.
    - reference: PMID:26743572
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "This 0.6-Mb inversion splits the 186-kb F8 into two parts with opposite transcription directions."
      explanation: This explains the structural mechanism by which Inv22 disrupts F8 transcription.
  features: >-
    Pathogenic F8 variants reduce or abolish functional factor VIII, with severe
    disease commonly caused by intron 22 inversion and other high-impact
    loss-of-function alleles.
  evidence:
  - reference: PMID:26743572
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HA is caused by a deficiency of the clotting factor VIII (FVIII), encoded by the factor VIII gene (F8)"
    explanation: This supports F8 as the causal gene and factor VIII deficiency as the immediate molecular defect.
  - reference: CGGV:assertion_d4578f11-b635-45f4-8034-310fca5fe960-2019-07-24T160000.000Z
    reference_title: "F8 / hemophilia A (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "F8 | HGNC:3546 | hemophilia A | MONDO:0010602 | XL | Definitive"
    explanation: ClinGen classifies the F8-hemophilia A gene-disease relationship as definitive with X-linked inheritance.
  notes: X-linked recessive, intron 22 inversion is a common severe mutation
treatments:
- name: Factor VIII Replacement
  description: Recombinant or plasma-derived factor VIII concentrate for bleeding episodes and prophylaxis.
  treatment_term:
    preferred_term: coagulation factor VIII replacement therapy
    term:
      id: MAXO:0020000
      label: coagulation factor VIII replacement therapy
  target_mechanisms:
  - target: Factor VIII Deficiency
    treatment_effect: RESTORES
    description: Replaces missing or deficient factor VIII activity upstream of intrinsic tenase dysfunction.
  evidence:
  - reference: PMID:31846611
    reference_title: "Factor VIII replacement is still the standard of care in haemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals."
    explanation: Review directly supports FVIII replacement prophylaxis as standard-of-care hemophilia A treatment.
- name: Emicizumab
  description: Bispecific antibody mimicking factor VIII function, subcutaneous prophylaxis.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_mechanisms:
  - target: Intrinsic Tenase Dysfunction
    treatment_effect: BYPASSES
    description: Bridges activated factor IX and factor X to substitute for missing activated factor VIII cofactor function.
  evidence:
  - reference: PMID:30157389
    reference_title: "Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors."
    supports: SUPPORT
    snippet: "Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis."
    explanation: Phase 3 HAVEN 3 trial demonstrates emicizumab mechanism and efficacy in hemophilia A without inhibitors.
- name: Immune Tolerance Induction
  description: Repeated FVIII administration protocol intended to downregulate anti-FVIII antibodies and eradicate inhibitors.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_mechanisms:
  - target: Alloimmune FVIII Inhibitor Response
    treatment_effect: INHIBITS
    description: Repeated FVIII exposure under immune tolerance protocols downregulates the established inhibitor response.
  evidence:
  - reference: PMID:29482894
    reference_title: "Review of immune tolerance induction in hemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using a protocol called \"immune tolerance induction\" (ITI), the repeated and frequent administration of FVIII under non-inflammatory conditions downregulates the established antibody response and induces immune tolerance."
    explanation: Review directly supports ITI as an inhibitor-eradication strategy for hemophilia A.
  - reference: PMID:26770953
    reference_title: "Immune tolerance induction in patients with severe hemophilia A with inhibitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complete tolerance was achieved in 14 of 17 patients (83%)."
    explanation: Retrospective severe hemophilia A inhibitor cohort quantifies ITI success, supporting the expected 60-80% range from the research artifact.
- name: Bypass Therapy
  description: Activated prothrombin complex concentrate or recombinant activated factor VII for bleeding in patients with active inhibitors.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_mechanisms:
  - target: Intrinsic Tenase Dysfunction
    treatment_effect: BYPASSES
    description: aPCC and rFVIIa promote hemostasis through alternative coagulation activation when FVIII activity is inhibited.
  evidence:
  - reference: PMID:22285208
    reference_title: "Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Activated prothrombin complex concentrate (aPCC) and recombinant Factor VIIa (rFVIIa) are 2 bypassing agents commonly used for treating acute bleeds in hemophiliac patients with inhibitors."
    explanation: Systematic review directly identifies aPCC and rFVIIa as bypassing agents for acute bleeding in hemophilia patients with inhibitors.
- name: Desmopressin (DDAVP)
  description: Releases endogenous factor VIII, useful in mild hemophilia A.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_mechanisms:
  - target: Factor VIII Deficiency
    treatment_effect: RESTORES
    description: Raises endogenous factor VIII availability in responsive non-severe hemophilia A.
  evidence:
  - reference: PMID:12640572
    reference_title: "Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety."
    supports: SUPPORT
    snippet: "Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction."
    explanation: Review confirms desmopressin as a widely used hemostatic agent in mild hemophilia A.
- name: Antifibrinolytics
  description: Tranexamic acid or aminocaproic acid as adjunctive therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:26704192
    reference_title: "Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions."
    supports: SUPPORT
    snippet: "Overall, the two included trials showed a beneficial effect of tranexamic acid and EACA, administered systemically, in reducing the number of bleedings, the amount of blood loss and the need for therapeutic clotting factor concentrates."
    explanation: Cochrane systematic review confirms beneficial effect of tranexamic acid and aminocaproic acid in reducing bleeding in hemophilia patients.
- name: Gene Therapy
  description: Emerging treatment using AAV vectors to deliver functional F8 gene.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: Factor VIII Deficiency
    treatment_effect: RESTORES
    description: Supplies a functional F8 expression cassette to restore endogenous factor VIII production.
  evidence:
  - reference: PMID:35294811
    reference_title: "Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A."
    supports: SUPPORT
    snippet: "In patients with severe hemophilia A, valoctocogene roxaparvovec treatment provided endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis."
    explanation: Phase 3 GENEr8-1 trial demonstrates AAV5-based gene therapy efficacy in severe hemophilia A.
classifications:
  harrisons_chapter:
  - classification_value: hematologic disorder
  - classification_value: coagulation disorder
  - classification_value: hereditary disease
datasets:
📚

References & Deep Research

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 44 citations 2026-04-25T22:31:58.187524

1. Disease Information

1.1 Concise overview (current understanding)

Recent primary genetics literature provides a concise definitional statement suitable for a KB entry: “Hemophilia A (HA, OMIM#306700) is an X‑linked recessive bleeding disorder caused by the defects in the F8 gene, which encodes coagulation factor VIII (FVIII).” (li2023f8geneinversion pages 1-2)

Severity is defined by baseline FVIII activity; a 2024 expert review lists: mild 0.05–0.4 IU/mL (6%–40%), moderate 0.01–0.05 IU/mL (2%–5%), and severe <0.01 IU/mL (<1%), with spontaneous bleeding characteristic of severe disease. (gupta2024expertopinionson pages 1-2)

1.2 Key identifiers (as available from retrieved sources)

  • OMIM: 306700 (Hemophilia A) (li2023f8geneinversion pages 1-2, liu2023comprehensiveanalysisof pages 1-2)
  • Causal gene: F8 (Factor VIII) (li2023f8geneinversion pages 1-2, chernyi2024recentadvancesin pages 1-3)

Not available in retrieved full text evidence: MONDO ID, Orphanet ID, ICD‑10/ICD‑11 codes, MeSH ID. These are commonly available from OMIM/Orphanet/MeSH but were not present in the retrieved documents, so they are not asserted here.

1.3 Synonyms and alternative names

  • Hemophilia A; HA (li2023f8geneinversion pages 1-2, gupta2024expertopinionson pages 1-2)
  • Factor VIII deficiency / coagulation factor VIII deficiency (explicitly used as description/synonym) (li2023f8geneinversion pages 1-2)

1.4 Evidence provenance (patient-level vs aggregated)

The evidence in this report is derived from: * Aggregated resources: systematic reviews/meta-analyses and narrative reviews (e.g., emicizumab meta-analysis; gene therapy reviews) (prudente2024emicizumabprophylaxisin pages 6-7, deshpande2024adenoassociatedvirus–basedgene pages 1-2) * Clinical trial datasets: phase 3 GENEr8‑1 long-term follow-up and related analyses (leavitt2024efficacysafetyand pages 1-2, long2024clinicalimmunogenicityoutcomes pages 1-2) * Single-center patient series: perioperative outcomes on emicizumab (rener2023managementandoutcomes pages 1-2) * Molecular diagnostic cohorts: regional/country genetics studies (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variants in F8, which encodes FVIII; HA is X‑linked recessive. (li2023f8geneinversion pages 1-2, chernyi2024recentadvancesin pages 1-3)

2.2 Risk factors

Genetic risk factors

  • High-impact F8 variants (e.g., deletions or nonsense variants) are noted to influence risk of developing inhibitory antibodies (inhibitors) to FVIII. A 2024 gene-therapy review states: “risk of developing inhibitory antibodies is influenced by genetic factors such as gene deletion or nonsense mutation on FVIII, as well as ethnicity.” (chernyi2024recentadvancesin pages 3-4)
  • A 2024 expert review notes inhibitors can develop in up to ~30% in severe HA. (gupta2024expertopinionson pages 2-3)

Environmental/clinical risk factors

No specific environmental causal risk factor is established for congenital HA itself (genetic disorder). However, treatment exposure (repeated FVIII infusions) is tied to inhibitor formation risk and to historical infection risks in the plasma-derived era. (chernyi2024recentadvancesin pages 3-4)

2.3 Protective factors

No protective genetic variants were identified in the retrieved evidence. Clinically, achieving higher steady FVIII activity reduces spontaneous bleeding risk; Roctavian review notes FVIII levels ~12%–20% protect against spontaneous hemorrhage and joint bleeds. (samelsonjones2024roctaviangenetherapy pages 1-2)

2.4 Gene–environment interactions

Not specifically addressed in retrieved evidence for congenital HA.

3. Phenotypes

3.1 Core phenotype spectrum (current understanding)

  • Bleeding diathesis ranging from trauma-related to spontaneous bleeds depending on baseline FVIII activity; spontaneous bleeding is characteristic of severe disease (<1% FVIII). (gupta2024expertopinionson pages 1-2, li2023f8geneinversion pages 1-2)
  • Hemarthroses and hemophilic arthropathy are key complications; patients with inhibitors have greater morbidity including arthropathy and worse quality of life. (prudente2024emicizumabprophylaxisin pages 6-7)

3.2 Phenotype characteristics

Age of onset

Severe HA often presents early in life; an adult cohort study notes severe cases are “often diagnosed within the first two years of life,” while mild cases may be diagnosed later. (vasava2024astudyof pages 5-6)

Severity and progression

Severity is largely determined by baseline FVIII activity (mild/moderate/severe). (gupta2024expertopinionson pages 1-2) Progression is driven by recurrent bleeding (especially joints), which can lead to chronic arthropathy. (prudente2024emicizumabprophylaxisin pages 6-7)

3.3 Quality-of-life impact

A 2024 phase 3 gene-therapy follow-up reports sustained, clinically meaningful improvement in hemophilia-specific HRQoL after valoctocogene roxaparvovec at 4 years (Haemophilia-Specific Quality of Life Questionnaire total score change significant). (leavitt2024efficacysafetyand pages 1-2)

3.4 Suggested HPO terms (examples)

Because retrieved texts did not provide an explicit HPO mapping, below are suggested HPO concepts for KB normalization (not directly asserted by cited sources): * Hemarthrosis / joint bleeding: HP:0003065 (Hemarthrosis) * Abnormal bleeding: HP:0001892 (Bleeding) * Prolonged activated partial thromboplastin time: HP:0003645 (Abnormality of partial thromboplastin time) * Hemophilic arthropathy: can be represented via arthropathy terms (e.g., HP:0002758 Arthritis) + site qualifiers.

Limitation: phenotype frequency-by-HPO (percent affected) could not be robustly extracted from the retrieved evidence corpus.

4. Genetic / Molecular Information

4.1 Causal genes

  • F8 (Factor VIII) is the causal gene for congenital hemophilia A. (li2023f8geneinversion pages 1-2, chernyi2024recentadvancesin pages 1-3)

Gene locus and structure: F8 is located at Xq28 and comprises 26 exons and 25 introns (~186–187 kb), per molecular diagnostic studies. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)

4.2 Pathogenic variants (variant classes and frequencies)

Hemophilia A shows extensive allelic heterogeneity (thousands of variants catalogued). (zhang2023moleculardiagnosisof pages 1-2)

Key recurrent structural variants in severe HA: * Intron 22 inversion (Inv22 / IVS22): approximately 45% of severe HA. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2) * Intron 1 inversion (Inv1 / IVS1): approximately 1–2% of severe HA. (zhang2023moleculardiagnosisof pages 1-2)

Representative abstract quote supporting Inv22 frequency: “Intron 22 inversion (Inv22) is found in about 45% of patients with severe hemophilia A.” (li2023f8geneinversion pages 1-2)

4.3 Variant detection approaches (molecular diagnostics)

A 2023 molecular study describes a standard workflow: FVIII activity (FVIII:C) by one-stage clotting assay, inhibitor titer by Bethesda assay, and genetic testing by inversion-specific PCR methods plus NGS with Sanger confirmation. (zhang2023moleculardiagnosisof pages 1-2)

4.4 Modifier genes / epigenetics

No congenital HA modifier genes or epigenetic mechanisms were identified in the retrieved evidence set.

4.5 Chromosomal abnormalities

Not a dominant mechanism in retrieved evidence beyond F8 inversions/large rearrangements. (zhang2023moleculardiagnosisof pages 1-2)

5. Environmental Information

5.1 Environmental factors

Congenital HA is genetic; no environmental causes were identified. Historical treatment-related infectious risk is documented (HIV/HCV in the 1980s era of plasma products). A 2024 review notes: “Up to 60–70% of individuals with severe hemophilia were found to have contracted HIV in the 1980s, and nearly all of them contracted hepatitis C.” (chernyi2024recentadvancesin pages 3-4)

5.2 Lifestyle factors / infectious agents

Not applicable as primary causal factors for congenital HA; infection risk pertains to past treatment-era blood product exposure. (chernyi2024recentadvancesin pages 3-4)

6. Mechanism / Pathophysiology

6.1 Causal chain (genotype → phenotype)

  1. F8 pathogenic variant → reduced/absent FVIII expression or activity. (li2023f8geneinversion pages 1-2)
  2. Low FVIII → impaired intrinsic pathway amplification and reduced capacity to generate stable clotting (clinically manifested as prolonged bleeding; severe disease shows spontaneous bleeds). (gupta2024expertopinionson pages 1-2, li2023f8geneinversion pages 1-2)
  3. Recurrent bleeding, particularly into joints → chronic joint damage (hemophilic arthropathy) and reduced quality of life. (prudente2024emicizumabprophylaxisin pages 6-7)
  4. Therapeutic FVIII exposure can induce FVIII inhibitors (alloantibodies) that neutralize infused FVIII, increasing bleeding morbidity and mortality. (prudente2024emicizumabprophylaxisin pages 6-7, gupta2024expertopinionson pages 2-3)

6.2 Key molecular/therapeutic mechanisms (2023–2024 understanding)

  • Emicizumab mechanism: a bispecific antibody that “bridges the gap between activated factor IX and factor X to replace the missing activated factor VIII.” (chernyi2024recentadvancesin pages 5-6)
  • Gene therapy mechanism: hepatotropic AAV gene addition to enable endogenous expression of B‑domain deleted FVIII; key limitation highlighted is declining FVIII expression over time after Roctavian. (samelsonjones2024roctaviangenetherapy pages 1-2)
  • Physiologic FVIII-producing cells: liver sinusoidal endothelial cells (LSEC) are a natural FVIII source; a 2024 EMBO Mol Med study states: “Coagulation factor VIII (FVIII), the gene mutated in hemophilia A, is naturally expressed by LSEC.” (milani2024gp64pseudotypedlentiviralvectors pages 1-2)

6.3 Suggested ontology terms

GO (Biological Process) – suggestions

  • blood coagulation (GO:0007596)
  • hemostasis (GO:0007599)
  • regulation of thrombin generation (GO term family; specific mapping may be needed)
  • immune response to foreign protein (for inhibitor formation)

CL (Cell Ontology) – suggestions

  • liver sinusoidal endothelial cell (LSEC)
  • hepatocyte
  • macrophage / Kupffer cell
  • megakaryocyte / platelet lineage (for platelet-targeted FVIII concepts)

UBERON – suggestions

  • liver (UBERON:0002107)
  • synovial joint (UBERON:0000978)

7. Anatomical Structures Affected

Organ/system level

  • Blood / hemostasis system (primary)
  • Joints (hemarthroses → arthropathy) (prudente2024emicizumabprophylaxisin pages 6-7)

Tissue/cell level

  • Liver-relevant tissues for gene therapy and endogenous FVIII production include hepatocytes and LSEC (milani2024gp64pseudotypedlentiviralvectors pages 1-2)

8. Temporal Development

  • Onset: congenital; severe disease often recognized early in childhood (often within first two years), while mild disease may be diagnosed later. (vasava2024astudyof pages 5-6)
  • Course: chronic lifelong without disease-modifying cure; modern prophylaxis and gene therapy aim to reduce or eliminate bleeding episodes. (leavitt2024efficacysafetyand pages 1-2)

9. Inheritance and Population

9.1 Inheritance

  • X‑linked recessive inheritance (li2023f8geneinversion pages 1-2)

9.2 Epidemiology (recent statistics)

  • Incidence estimates include ~1 in 5,000 male births. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)
  • A 2024 immunogenicity paper states incidence as “24.6 out of 100,000 males.” (long2024clinicalimmunogenicityoutcomes pages 1-2)
  • Regional prevalence example: pooled prevalence in Africa 6.82 per 100,000 persons (95% CI 5.16–8.48). (chernyi2024recentadvancesin pages 1-3)

Limitation: detailed age distribution, ethnicity-specific prevalence, and global registry-derived prevalence/incidence were not directly retrievable from the available full-text evidence.

10. Diagnostics

10.1 Clinical and laboratory testing

  • Screening often begins with prolonged aPTT, while PT and platelet count can be normal; confirmatory testing measures FVIII activity. (gupta2024expertopinionson pages 2-3)
  • FVIII activity measurement:
  • One-stage aPTT-based clotting assay is the most common worldwide. (bowyer2023factorviiiand pages 1-2)
  • Chromogenic substrate assays are used in specialized labs; one-stage vs chromogenic assays can disagree in mild HA and for some therapies, including gene therapy monitoring. (bowyer2023factorviiiand pages 1-2)

10.2 Inhibitor testing

  • Inhibitor titers can be quantified using the Bethesda assay (explicitly described in 2023 molecular diagnostic work). (zhang2023moleculardiagnosisof pages 1-2)

10.3 Genetic testing

A 2023 diagnostic study lists commonly used inversion detection methods (e.g., inverse-shift PCR, long-distance PCR), and documents use of long-range PCR/multiplex PCR for Inv22/Inv1 plus NGS and Sanger confirmation for other variants. (zhang2023moleculardiagnosisof pages 1-2)

A 2024 expert review emphasizes that >3,500 pathogenic F8 variants are reported, and that NGS and Sanger sequencing improve diagnostic yield and can enable preimplantation genetic diagnosis. (gupta2024expertopinionson pages 15-16)

10.4 Differential diagnosis

Not systematically addressed for congenital HA in retrieved evidence (acquired hemophilia A and other causes of prolonged aPTT are discussed in other literature, but not part of this congenital HA evidence set).

11. Outcome / Prognosis

Modern outcomes (bleeding control)

Long-term phase 3 data show gene therapy can substantially reduce bleeding and factor usage at 4 years, with many participants experiencing zero treated bleeds in year 4. (leavitt2024efficacysafetyand pages 1-2)

Limitation: explicit life expectancy, all-cause mortality, and cause-specific mortality rates were not provided in the retrieved evidence.

12. Treatment

12.1 Standard of care: factor replacement

Regular FVIII replacement (standard or extended half-life products) remains a core prophylaxis approach; limitations include IV administration burden and inhibitor development. (gupta2024expertopinionson pages 2-3, gupta2024expertopinionson pages 1-2)

MAXO suggestions: * clotting factor replacement therapy (MAXO term family) * prophylactic treatment (MAXO:0000069; confirm exact term mapping in MAXO)

12.2 Non-factor prophylaxis: emicizumab

Evidence of effectiveness: A 2024 systematic review/meta-analysis in people with HA and inhibitors found lower treated-bleed ABR on emicizumab vs bypassing agents, with standardized mean difference −1.58 (95% CI −2.50 to −0.66; P=0.0008). (prudente2024emicizumabprophylaxisin pages 6-7)

Safety considerations: the same review notes thrombotic events/TMA have been associated with concurrent high-dose aPCC for >1 day; anti-drug antibodies were reported and emicizumab can persist for ~6 months. (prudente2024emicizumabprophylaxisin pages 6-7)

Real-world implementation: A 2023 single-center perioperative series (12 procedures in 8 adults on emicizumab) reported no major bleeds, thrombotic events, deaths, or new inhibitors, supporting feasibility of surgery with appropriate adjunct hemostasis. (rener2023managementandoutcomes pages 1-2)

MAXO suggestions: * monoclonal antibody therapy * bleeding prophylaxis

12.3 Inhibitors and immune tolerance induction (ITI)

A 2024 gene-therapy review reports ITI success is ~60%–80%, while 20%–40% of severe HA patients do not achieve tolerance, with predictors including high peak inhibitor titer and prior failed ITI. (chernyi2024recentadvancesin pages 3-4)

MAXO suggestions: * immune tolerance induction therapy

12.4 Advanced therapeutics: AAV gene therapy (Roctavian / valoctocogene roxaparvovec)

Regulatory status: Roctavian was conditionally approved in Europe (Aug 2022) and approved in the US (June 2023). (samelsonjones2024roctaviangenetherapy pages 1-2)

Efficacy at 4 years (GENEr8‑1): mean treated ABR reduced −82.6% and annualized FVIII infusion rate reduced −95.5% vs baseline; in year 4, 81/110 rollover participants had 0 treated bleeds. Week‑208 chromogenic FVIII activity mean 16.1 IU/dL, median 6.7 IU/dL. (leavitt2024efficacysafetyand pages 1-2)

Comparative effectiveness: a propensity-score comparison reports treated ABR 4.40 vs 0.85 and all-bleed ABR 5.01 vs 1.54 (FVIII prophylaxis vs valoctocogene roxaparvovec), and zero treated bleeds in 32.9% vs 82.1% (controls vs treated). (leavitt2024efficacysafetyand pages 1-2)

Immunogenicity: “No FVIII inhibitors were detected following administration of valoctocogene roxaparvovec,” and all participants developed durable anti-AAV5 antibodies; pre-existing anti-AAV5 antibodies occur in 29.7% of people with HA globally. (long2024clinicalimmunogenicityoutcomes pages 1-2)

Liver safety / monitoring: ALT elevations are common; GENEr8‑1 year‑4 data report ALT elevation as the most common adverse event (56/131 participants in year 4). (leavitt2024efficacysafetyand pages 1-2)

A 2024 Blood Advances expert guidance paper provides detailed visual guidance for liver monitoring and management of ALT elevations after Roctavian (eligibility workup, monitoring schedule, and a corticosteroid management algorithm). (mura2024liverrelatedaspectsof media 8f4fbc2d, mura2024liverrelatedaspectsof media 4d9b2f5b, mura2024liverrelatedaspectsof media 179ecf90)

13. Prevention

Genetic counseling and reproductive options

A 2024 expert review recommends genetic analysis to identify carriers and support counseling; it notes chorionic villous sampling at 11–14 weeks in carrier pregnancies and that NGS/Sanger sequencing support molecular diagnosis and preimplantation genetic diagnosis approaches. (gupta2024expertopinionson pages 15-16)

Tertiary prevention (preventing complications)

Prophylaxis to minimize bleeding is emphasized as a strategy to prevent morbidity (e.g., arthropathy), including early prophylaxis approaches. (gupta2024expertopinionson pages 2-3)

14. Other Species / Natural Disease

The retrieved evidence did not explicitly document naturally occurring hemophilia A in companion animals; it does support broader comparative models including dogs with hemophilia A used in research. (chernyi2024recentadvancesin pages 6-8)

15. Model Organisms

15.1 Common models

  • Hemophilia A mouse models, including Alb‑F8*R593C strain used for gene-therapy studies. (milani2024gp64pseudotypedlentiviralvectors pages 14-15)
  • Dogs with hemophilia A as large-animal translational models. (chernyi2024recentadvancesin pages 6-8)

15.2 Mechanistic relevance of cell types

A 2024 experimental gene-therapy study emphasizes LSECs as physiologic FVIII producers and demonstrates correction of hemophilia A mice by targeting FVIII expression to liver endothelium. (milani2024gp64pseudotypedlentiviralvectors pages 1-2)

Recent developments and real-world implementations (2023–2024 highlights)

  1. Emicizumab continues to expand real-world use, including perioperative management with favorable outcomes in a single-center series and improved bleed prophylaxis vs bypassing agents in inhibitor populations. (prudente2024emicizumabprophylaxisin pages 6-7, rener2023managementandoutcomes pages 1-2)
  2. Licensed gene therapy (Roctavian) is supported by 4‑year phase 3 outcomes demonstrating sustained reductions in ABR and factor usage, but with clinically important considerations around ALT elevations and monitoring, plus unanswered questions around FVIII expression durability declines. (samelsonjones2024roctaviangenetherapy pages 1-2, leavitt2024efficacysafetyand pages 1-2, mura2024liverrelatedaspectsof media 8f4fbc2d)

Key quantitative findings table (2023–2024)

Topic Key findings (include numbers) Population/setting Year Source (journal) URL PMID if available Evidence citation ID
Epidemiology Hemophilia A incidence in males is about 1/5,000; one review also reports incidence as 24.6 per 100,000 males General population / congenital HA 2023-2024 Global Medical Genetics; Molecular Therapy https://doi.org/10.1055/s-0043-1774322 ; https://doi.org/10.1016/j.ymthe.2024.05.033 (zhang2023moleculardiagnosisof pages 1-2, long2024clinicalimmunogenicityoutcomes pages 1-2)
Epidemiology Pooled prevalence of HA in Africa: 6.82 cases per 100,000 persons (95% CI 5.16-8.48) Systematic review/meta-analysis of 15 African studies 2024 BMC Public Health https://doi.org/10.1186/s12889-024-20165-w (chernyi2024recentadvancesin pages 1-3)
Genetics Intron 22 inversion (Inv22) is found in about 45% of severe HA; intron 1 inversion accounts for about 1-2% of severe HA Severe congenital HA 2023 Frontiers in Genetics; Global Medical Genetics https://doi.org/10.3389/fgene.2023.1098795 ; https://doi.org/10.1055/s-0043-1774322 (zhang2023moleculardiagnosisof pages 1-2)
Genetics In a Belarus cohort, 20.4% had inhibitor history; among severe HA, 45.1% (37/82) had Inv22 and 1.2% (1/82) had Inv1; pathogenic F8 variants identified in 99% (97/98) 98 patients with HA in Belarus 2023 Pediatric Hematology/Oncology and Immunopathology https://doi.org/10.24287/1726-1708-2023-22-3-48-57 (zhang2023moleculardiagnosisof pages 1-2)
Diagnostics FVIII activity and VWF antigen measured by one-stage clotting assay; inhibitor titers quantified by Bethesda assay; inversion testing by long-range PCR/multiplex PCR, with NGS plus Sanger confirmation for non-inversion variants Molecular diagnosis workflow in congenital HA 2023 Global Medical Genetics https://doi.org/10.1055/s-0043-1774322 (zhang2023moleculardiagnosisof pages 1-2)
Diagnostics The one-stage aPTT-based assay is the most commonly used worldwide; chromogenic substrate assays are available in specialized labs; assay choice can materially change FVIII results, including in mild HA and during monitoring of replacement products or gene therapy Laboratory diagnosis/monitoring of HA 2023 Seminars in Thrombosis and Hemostasis https://doi.org/10.1055/s-0042-1758870 (bowyer2023factorviiiand pages 1-2)
Treatment In severe HA, inhibitors develop in up to ~30%; current ITI success is about 60%-80%, leaving 20%-40% unsuccessful Severe congenital HA with inhibitors 2024 Biomolecules; Cureus https://doi.org/10.3390/biom14070854 ; https://doi.org/10.7759/cureus.c172 (chernyi2024recentadvancesin pages 3-4, gupta2024expertopinionson pages 2-3)
Emicizumab safety/effectiveness Compared with bypassing-agent prophylaxis, emicizumab reduced treated-bleed ABR with standardized mean difference -1.58 (95% CI -2.50 to -0.66, P=0.0008); BPA effectiveness reported at ~60%-72%, and up to 20% of bleeds may remain uncontrolled on standard BPA regimens Systematic review/meta-analysis in PwHA with inhibitors 2024 São Paulo Medical Journal https://doi.org/10.1590/1516-3180.2023.0102.r1.20022024 (prudente2024emicizumabprophylaxisin pages 6-7)
Emicizumab safety/effectiveness In a perioperative real-world series, 12 procedures in 8 adults on emicizumab (3 minor, 9 major) had no major bleeds, thrombotic events, deaths, or new inhibitors Single-center invasive-procedure cohort 2023 Hematology Reports https://doi.org/10.3390/hematolrep15040062 (rener2023managementandoutcomes pages 1-2)
Gene therapy In phase 3 GENEr8-1, valoctocogene roxaparvovec achieved -82.6% reduction in treated ABR and -95.5% reduction in annualized FVIII infusion rate at 4 years; during year 4, 81/110 rollover participants had 0 treated bleeds; week-208 chromogenic FVIII activity mean 16.1 IU/dL, median 6.7 IU/dL 134 adult males with severe HA, no inhibitors 2024 Research and Practice in Thrombosis and Haemostasis https://doi.org/10.1016/j.rpth.2024.102615 (leavitt2024efficacysafetyand pages 1-2)
Gene therapy Propensity-score comparison: mean treated ABR 4.40 vs 0.85 and all-bleed ABR 5.01 vs 1.54 for FVIII prophylaxis vs valoctocogene roxaparvovec; zero treated bleeds in 82.1% vs 32.9% and zero all bleeds in 58.0% vs 28.5% Severe HA: GENEr8-1 treated cohort vs contemporaneous FVIII-prophylaxis controls 2024 Advances in Therapy https://doi.org/10.1007/s12325-024-02834-9 (leavitt2024efficacysafetyand pages 1-2)
Gene therapy safety After valoctocogene roxaparvovec, no FVIII inhibitors were detected; all participants developed durable anti-AAV5 antibodies; pre-existing anti-AAV5 antibodies occur in 29.7% of people with HA globally Phase 3 GENEr8-1 immunogenicity analysis 2024 Molecular Therapy https://doi.org/10.1016/j.ymthe.2024.05.033 (long2024clinicalimmunogenicityoutcomes pages 1-2)
Gene therapy safety In year 4 of GENEr8-1, ALT elevation was the most common adverse event: 56/131 participants; another expert guidance source notes 88.8% of GENEr8-1 participants had ALT elevations overall Post-gene-therapy liver safety monitoring 2024 Research and Practice in Thrombosis and Haemostasis; Blood Advances https://doi.org/10.1016/j.rpth.2024.102615 ; https://doi.org/10.1182/bloodadvances.2024013750 (leavitt2024efficacysafetyand pages 1-2, mura2024liverrelatedaspectsof media 8f4fbc2d)

Table: This table compiles key quantitative 2023-2024 findings for congenital Hemophilia A across epidemiology, F8 genetics, diagnostic assays, emicizumab use, and gene therapy. It is useful as a quick evidence map for populating a disease knowledge base with recent, citable data.

Notes on evidence gaps

  • MONDO/Orphanet/ICD/MeSH identifiers were not present in the retrieved documents and thus are not verified here.
  • Many phenotype frequencies and long-term survival/life expectancy outcomes are typically available in registries (e.g., WFH, national registries) but were not accessible in the retrieved full-text corpus.
  • 2023–2024 primary trial outcome data for other non-factor agents (e.g., fitusiran, concizumab) were not present in retrievable full texts; this report therefore focuses on emicizumab and valoctocogene roxaparvovec, which were well supported.

References

  1. (li2023f8geneinversion pages 1-2): Shaoying Li, Jianchun He, Liming Chu, Shuai Ren, Wenzhi He, Xiaoyan Ma, Yanchao Wang, Mincong Zhang, Lingyin Kong, Bo Liang, and Qing Li. F8 gene inversion and duplication cause no obvious hemophilia a phenotype. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1098795, doi:10.3389/fgene.2023.1098795. This article has 4 citations and is from a peer-reviewed journal.

  2. (gupta2024expertopinionson pages 1-2): Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M. J. John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, and Vijay Shah. Expert opinions on the management of hemophilia a in india: the role of emicizumab. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.c172, doi:10.7759/cureus.c172. This article has 13 citations.

  3. (liu2023comprehensiveanalysisof pages 1-2): Yingdi Liu, Dongzhi Li, Dongyi Yu, Qiaowei Liang, Guilan Chen, Fucheng Li, Lu Gao, Zhuo Li, Tiantian Xie, Le Wu, Aiping Mao, Lingqian Wu, and Desheng Liang. Comprehensive analysis of hemophilia a (cahea): towards full characterization of the f8 gene variants by long-read sequencing. Thrombosis and Haemostasis, 123:1151-1164, Jun 2023. URL: https://doi.org/10.1055/a-2107-0702, doi:10.1055/a-2107-0702. This article has 28 citations and is from a domain leading peer-reviewed journal.

  4. (chernyi2024recentadvancesin pages 1-3): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

  5. (prudente2024emicizumabprophylaxisin pages 6-7): Tiago Paiva Prudente, Ricardo Mesquita Camelo, Rafael Alves Guimarães, and Maria do Rosário Ferraz Roberti. Emicizumab prophylaxis in people with hemophilia a and inhibitors: a systematic review and meta-analysis. São Paulo Medical Journal, May 2024. URL: https://doi.org/10.1590/1516-3180.2023.0102.r1.20022024, doi:10.1590/1516-3180.2023.0102.r1.20022024. This article has 1 citations.

  6. (deshpande2024adenoassociatedvirus–basedgene pages 1-2): Saarang R. Deshpande, Keerthy Joseph, Jiayi Tong, Yong Chen, Allyson Pishko, and Adam Cuker. Adeno-associated virus–based gene therapy for hemophilia a and b: a systematic review and meta-analysis. Blood Advances, 8:5957-5974, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024014111, doi:10.1182/bloodadvances.2024014111. This article has 27 citations and is from a peer-reviewed journal.

  7. (leavitt2024efficacysafetyand pages 1-2): Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington, Doris V. Quon, Adam Giermasz, Maria Fernanda López Fernández, Gili Kenet, Gillian Lowe, Nigel S. Key, Carolyn M. Millar, Steven W. Pipe, Bella Madan, Sheng-Chieh Chou, Robert Klamroth, Jane Mason, Hervé Chambost, Flora Peyvandi, Elaine Majerus, Dominic Pepperell, Christine Rivat, Hua Yu, Tara M. Robinson, and Margareth C. Ozelo. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia a in the phase 3 gener8-1 trial. Research and Practice in Thrombosis and Haemostasis, 8:102615, Nov 2024. URL: https://doi.org/10.1016/j.rpth.2024.102615, doi:10.1016/j.rpth.2024.102615. This article has 37 citations and is from a peer-reviewed journal.

  8. (long2024clinicalimmunogenicityoutcomes pages 1-2): Brian R. Long, Tara M. Robinson, Jonathan R.S. Day, Hua Yu, Kelly Lau, Urooj Imtiaz, Kathryn S. Patton, Greg de Hart, Joshua Henshaw, Suresh Agarwal, Christian Vettermann, Stephen J. Zoog, and Soumi Gupta. Clinical immunogenicity outcomes from gener8-1, a phase 3 study of valoctocogene roxaparvovec, an aav5-vectored gene therapy for hemophilia a. Molecular Therapy, 32:2052-2063, Jul 2024. URL: https://doi.org/10.1016/j.ymthe.2024.05.033, doi:10.1016/j.ymthe.2024.05.033. This article has 27 citations and is from a highest quality peer-reviewed journal.

  9. (rener2023managementandoutcomes pages 1-2): Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, and Irena Preložnik Zupan. Management and outcomes of invasive procedures in individuals with hemophilia a on emicizumab prophylaxis: a single center experience. Hematology Reports, 15:597-607, Nov 2023. URL: https://doi.org/10.3390/hematolrep15040062, doi:10.3390/hematolrep15040062. This article has 4 citations.

  10. (zhang2023moleculardiagnosisof pages 1-2): Xialin Zhang, Kun Chen, Sicheng Bian, Gang Wang, Xiuyu Qin, Ruijuan Zhang, and Linhua Yang. Molecular diagnosis of hemophilia a and pathogenesis of novel f8 variants in shanxi, china. Global Medical Genetics, 10:247-262, Sep 2023. URL: https://doi.org/10.1055/s-0043-1774322, doi:10.1055/s-0043-1774322. This article has 3 citations.

  11. (chernyi2024recentadvancesin pages 3-4): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

  12. (gupta2024expertopinionson pages 2-3): Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M. J. John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, and Vijay Shah. Expert opinions on the management of hemophilia a in india: the role of emicizumab. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.c172, doi:10.7759/cureus.c172. This article has 13 citations.

  13. (samelsonjones2024roctaviangenetherapy pages 1-2): Benjamin J. Samelson-Jones, Juliana C. Small, and Lindsey A. George. Roctavian gene therapy for hemophilia a. Blood Advances, 8:5179-5189, Oct 2024. URL: https://doi.org/10.1182/bloodadvances.2023011847, doi:10.1182/bloodadvances.2023011847. This article has 38 citations and is from a peer-reviewed journal.

  14. (vasava2024astudyof pages 5-6): Renuka Vasava, Minal Shastri, Vaishnavi M Rathod, Gayatri Laha, Vaishnovi Vaishnovi, Nipakumari J Patel, Rajani Deshagoni, Prerna Singh, Nandan Joshi, and Darshankumar M Raval. A study of clinical profile and treatment in adult hemophilia patients with special reference to the inhibitor levels. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54663, doi:10.7759/cureus.54663. This article has 2 citations.

  15. (chernyi2024recentadvancesin pages 5-6): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

  16. (milani2024gp64pseudotypedlentiviralvectors pages 1-2): Michela Milani, Cesare Canepari, S. Assanelli, Simone Merlin, Ester Borroni, Francesco Starinieri, Mauro Biffi, Fabio Russo, Anna Fabiano, Desirèe Zambroni, Andrea Annoni, L. Naldini, Antonia Follenzi, and Alessio Cantore. Gp64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia a mice. EMBO Molecular Medicine, 16:1427-1450, Apr 2024. URL: https://doi.org/10.1038/s44321-024-00072-8, doi:10.1038/s44321-024-00072-8. This article has 17 citations and is from a highest quality peer-reviewed journal.

  17. (bowyer2023factorviiiand pages 1-2): Annette E. Bowyer and Robert C. Gosselin. Factor viii and factor ix activity measurements for hemophilia diagnosis and related treatments. Seminars in Thrombosis and Hemostasis, 49:609-620, Dec 2023. URL: https://doi.org/10.1055/s-0042-1758870, doi:10.1055/s-0042-1758870. This article has 42 citations and is from a peer-reviewed journal.

  18. (gupta2024expertopinionson pages 15-16): Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M. J. John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, and Vijay Shah. Expert opinions on the management of hemophilia a in india: the role of emicizumab. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.c172, doi:10.7759/cureus.c172. This article has 13 citations.

  19. (mura2024liverrelatedaspectsof media 8f4fbc2d): Vincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, Adriano De Santis, Giovanni Di Minno, Luca Fabris, Fabio Marra, Filomena Morisco, Flora Peyvandi, Maurizio Pompili, Cristina Santoro, Ezio Zanon, and Giancarlo Castaman. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia a: expert guidance for clinical practice. Blood Advances, 8:5725-5734, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024013750, doi:10.1182/bloodadvances.2024013750. This article has 11 citations and is from a peer-reviewed journal.

  20. (mura2024liverrelatedaspectsof media 4d9b2f5b): Vincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, Adriano De Santis, Giovanni Di Minno, Luca Fabris, Fabio Marra, Filomena Morisco, Flora Peyvandi, Maurizio Pompili, Cristina Santoro, Ezio Zanon, and Giancarlo Castaman. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia a: expert guidance for clinical practice. Blood Advances, 8:5725-5734, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024013750, doi:10.1182/bloodadvances.2024013750. This article has 11 citations and is from a peer-reviewed journal.

  21. (mura2024liverrelatedaspectsof media 179ecf90): Vincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, Adriano De Santis, Giovanni Di Minno, Luca Fabris, Fabio Marra, Filomena Morisco, Flora Peyvandi, Maurizio Pompili, Cristina Santoro, Ezio Zanon, and Giancarlo Castaman. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia a: expert guidance for clinical practice. Blood Advances, 8:5725-5734, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024013750, doi:10.1182/bloodadvances.2024013750. This article has 11 citations and is from a peer-reviewed journal.

  22. (chernyi2024recentadvancesin pages 6-8): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

  23. (milani2024gp64pseudotypedlentiviralvectors pages 14-15): Michela Milani, Cesare Canepari, S. Assanelli, Simone Merlin, Ester Borroni, Francesco Starinieri, Mauro Biffi, Fabio Russo, Anna Fabiano, Desirèe Zambroni, Andrea Annoni, L. Naldini, Antonia Follenzi, and Alessio Cantore. Gp64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia a mice. EMBO Molecular Medicine, 16:1427-1450, Apr 2024. URL: https://doi.org/10.1038/s44321-024-00072-8, doi:10.1038/s44321-024-00072-8. This article has 17 citations and is from a highest quality peer-reviewed journal.